A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
about
Glutathione S-conjugates as prodrugs to target drug-resistant tumors.Therapeutic and analytical applications of arsenic binding to proteins.Dynamic contrast-enhanced MRI for oncology drug development.Glutathione transferase P1-1 as an arsenic drug-sequestering enzyme.Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges.
P2860
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A phase 1 trial of intravenous ...... s with advanced solid tumours.
@ast
A phase 1 trial of intravenous ...... s with advanced solid tumours.
@en
type
label
A phase 1 trial of intravenous ...... s with advanced solid tumours.
@ast
A phase 1 trial of intravenous ...... s with advanced solid tumours.
@en
prefLabel
A phase 1 trial of intravenous ...... s with advanced solid tumours.
@ast
A phase 1 trial of intravenous ...... s with advanced solid tumours.
@en
P2093
P2860
P50
P1476
A phase 1 trial of intravenous ...... s with advanced solid tumours.
@en
P2093
Alison Backen
Andrew Clamp
Andrew Taylor
Caleb Roberts
Cancer Research UK Drug Development Office Phase I clinical trial
Danielle Shaw
Gavin Halbert
Gireesh Kumaran
Hayley Farmer
Helen Turner
P2860
P2888
P304
P356
10.1007/S00280-013-2320-9
P577
2013-10-20T00:00:00Z